TIAdd image
Tesamorelin + Ipamorelin Blend
PerformanceBlendComponents: Tesamorelin, Ipamorelin
A potent GH-stimulation blend combining the stabilized GHRH analog Tesamorelin with selective GHRP Ipamorelin.
Half-life
1 h
Common dose
500 – 1000 mcg
Dosing frequency
Daily
Administration
Subcutaneous
How it works
Tesamorelin provides robust, sustained GHRH-receptor activation while Ipamorelin adds a clean ghrelin-receptor pulse. The blend is favored where visceral-fat reduction is a goal.
Protocol notes
Typical dosing ~500 mcg of each, daily pre-bed. Cycles of 12–26 weeks.
Reported side effects
Combined profile: joint pain, water retention, injection-site reactions.